Orchard Therapeutics Plc

Officers & Directors

Orchard Therapeutics Plc currently has 100 employees.

News about Orchard Therapeutics Plc Key Personnel

Orchard Therapeutics: Pioneering Breakthrough Treatment while Navigating Financial Waters

Orchard Therapeutics: Breakthrough Treatment for Metachromatic Leukodystrophy and Financial Challenges
In a groundbreaking development, Orchard Therapeutics has received FDA approval for its therapy, Lenmeldy (atidarsagene autotemcel), making it the sole treatment available for eligible children with Early-onset Metachromatic Leukodystrophy (MLD) in the United States. This one-time treatment has demonstrated the potential to restore enzymatic function and effectively halt or slow down the progression of the disease. With a median follow-up of 6.76 years and some patients followed for up to 12 years, Lenmeldy has shown promising long-term results.
Metachromatic Leukodystrophy is a rare genetic disorde...

Business Description

Officers & Directors

ORTX Management Effectiveness

ORTX Revenue per Employee

ORTX Income per Employee

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.